Abstract TP9: Examining Predictors Of Functional 90-day Outcome Among Stroke Patients With Active Cancer Receiving Endovascular Therapy

Abstract

Introduction: Intraarterial therapy (IAT) is the standard of care for all AIS patients, even those with active cancer. However, there is little information on the characteristics that may contribute to a functional 90-day modified Rankin scale (mRS 0-2) score for AIS patients with active cancer undergoing IAT. Methods: This retrospective study included patients (age ≥ 18) admitted from 07/18-10/20 with AIS and were treated by IAT. AIS patients with large artery occlusion who had active cancer were identified. Baseline characteristics and outcomes were evaluated to determine predictors of a functional outcome at 90 days. Outcomes were also compared to those without active cancer during the same period. The receiver operating characteristic area under the curve (AUC) was used to determine optimal admission national institutes of health scores (NIHSS) to obtain a 90-day mRS of 0-2. Results: Of the 453 patients who received IAT, 12% had active cancer. Overall, patients were a majority male (50%), a median of 70 (60-81) years of age and had an admission NIHSS of 14 (7-20). Compared to patients without cancer, patients with cancer experienced significantly more thromboembolic events during their hospital stay (40% vs. 11%, p<0.001), but functional outcomes at 90-days were not different between groups. In active cancer patients, an admission NIHSS cut-off of 8.2 (AUC:0.72 (confidence interval (CI): 0.58-0.86), p=0.001) indicating strong fit, and experiencing less thromboembolic events, were significantly associated with functional independency at 90 days. However, the admission NIHSS cut-off for patients without cancer for predicting a functional outcome was 10.5 (AUC: 0.66 (CI: 0.60-.71), p<0.001), indicating moderate fit. Receiving intravenous tissue type plasminogen activator (IV-tPA) and successful reperfusion were other significant predictors of a functional outcome for non-cancer patients. Conclusions: In our population, using an NIHSS cut-off of 8.2 for patients with active cancer in determining who should receive IAT may increase the probability of a favorable 90-day outcome. An admission NIHSS of 10.5 was moderately associated with functional outcome at 90 days, in addition to successful reperfusion and receiving IV-tPA in non-cancer patients.

Effect of 2% meloxicam injection in Holstein dairy cows on acute clinical mastitis without systemic symptoms

“…BK is a degradation product of high-molecular-weight kininogen in the kinin cascade catalyzed by kallikrein, which increases vasodilation, vascular permeability, and pain during tissue inflammation [ 12 ]. In our study, the whey BK concentrations of the T group ranged from 3.0–4.7 pg/mL from day 0 to day 2 and reached 12.2 pg/mL on day 3.…”

Bradykinin release following trauma and hemorrhagic shock causes pulmonary alveolar leak in a rodent model

“…Bradykinin is a nonapeptide product of high-molecular weight kininogen (HMWK) breakdown in the kinin-kallikrein axis and mediates various pathways including arteriolar vasodilation and increased vascular permeability 6,7 . Bradykinin is generated by several contact pathways including activation of the contact coagulation cascade involving coagulation factor XII (FXII) and HMWK, 8 cleavage of HMWK via plasmin activated by released tissue plasminogen activator (tPA), 9 and HMWK cleavage by proteases generated by neutrophil extracellular traps, 10 platelet polyphosphate (polyP) release, 11 and tissue kallikrein (KLK-1) 12 .…”